Oncologists 	Oncologists 	 NNP	B-NP
'  	'  	 POS	O
experiences  	experiences  	 NNS	O
with  	with  	 IN	O
drug  	drug  	 NN	B-NP
shortages  	shortages  	 NNS	I-NP
There  	There  	 EX	O
have  	have  	 VBP	O
been  	been  	 VBN	O
numerous  	numerous  	 JJ	B-NP
reports  	reports  	 NNS	I-NP
of  	of  	 IN	O
shortages  	shortages  	 NNS	O
of  	of  	 IN	O
injectable  	injectable  	 JJ	O
drugs  	drugs  	 NNS	O
for  	for  	 IN	O
cancer  	cancer  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
decade 	decade 	 NN	O
.  	.  	 .	O
We  	We  	 PRP	O
assessed  	assessed  	 VBD	B-NP
physician  	physician  	 NN	I-NP
experiences  	experiences  	 NNS	I-NP
with  	with  	 IN	O
drug  	drug  	 NN	B-NP
shortages  	shortages  	 NNS	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
population-based  	population-based  	 JJ	B-NP
cohort  	cohort  	 NN	I-NP
of  	of  	 IN	I-NP
medical  	medical  	 JJ	I-NP
oncologists  	oncologists  	 JJ	I-NP
caring  	caring  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
lung  	lung  	 NN	O
or  	or  	 CC	O
colorectal  	colorectal  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
surveyed  	surveyed  	 VBD	O
medical  	medical  	 JJ	B-NP
oncologists  	oncologists  	 JJ	I-NP
caring  	caring  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
lung  	lung  	 NN	O
or  	or  	 CC	O
colorectal  	colorectal  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
Cancer  	Cancer  	 NNP	B-NP
Care  	Care  	 NNP	I-NP
Outcomes  	Outcomes  	 NNP	I-NP
Research  	Research  	 NNP	I-NP
and  	and  	 CC	O
Surveillance  	Surveillance  	 NNP	B-NP
Consortium  	Consortium  	 NNP	I-NP
from  	from  	 IN	O
2012  	2012  	 CD	O
to  	to  	 TO	O
2013  	2013  	 CD	O
( 	( 	 -LRB-	O
participation  	participation  	 NN	B-NP
rate 	rate 	 NN	I-NP
,  	,  	 ,	O
53 	53 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Oncologists  	Oncologists  	 NNP	B-NP
reported  	reported  	 VBD	O
experiences  	experiences  	 VBN	O
with  	with  	 IN	O
shortages  	shortages  	 NNS	O
of  	of  	 IN	O
leucovorin 	leucovorin 	 NN	B-NP
,  	,  	 ,	O
fluorouracil 	fluorouracil 	 NN	B-NP
,  	,  	 ,	O
dexamethasone 	dexamethasone 	 NN	B-NP
,  	,  	 ,	O
cyanocobalamin 	cyanocobalamin 	 NN	B-NP
,  	,  	 ,	O
paclitaxel 	paclitaxel 	 NN	B-NP
,  	,  	 ,	O
cisplatin 	cisplatin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
etoposide  	etoposide  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
prior  	prior  	 JJ	O
year  	year  	 NN	O
and  	and  	 CC	O
whether  	whether  	 IN	O
they  	they  	 PRP	O
had  	had  	 VBD	O
used  	used  	 VBN	O
a  	a  	 DT	O
less-effective  	less-effective  	 JJ	B-NP
alternative  	alternative  	 NN	I-NP
because  	because  	 IN	O
of  	of  	 IN	O
a  	a  	 DT	O
shortage 	shortage 	 NN	O
.  	.  	 .	O
We  	We  	 PRP	O
used  	used  	 VBD	O
multivariable  	multivariable  	 JJ	B-NP
logistic  	logistic  	 JJ	I-NP
regression  	regression  	 NN	I-NP
to  	to  	 TO	O
assess  	assess  	 VB	O
for  	for  	 IN	O
associations  	associations  	 NNS	B-NP
between  	between  	 IN	O
physician  	physician  	 NN	O
or  	or  	 CC	O
practice  	practice  	 NN	B-NP
characteristics  	characteristics  	 NNS	I-NP
and  	and  	 CC	O
encountering  	encountering  	 JJ	O
shortages 	shortages 	 NNS	O
.  	.  	 .	O
Among  	Among  	 IN	O
330  	330  	 CD	O
respondents 	respondents 	 NNS	O
,  	,  	 ,	O
74 	74 	 CD	O
%  	%  	 NN	O
reported  	reported  	 VBD	O
experiences  	experiences  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
shortage  	shortage  	 NN	O
of  	of  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
one  	one  	 CD	O
drug  	drug  	 NN	O
in  	in  	 IN	O
our  	our  	 PRP$	O
survey 	survey 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
28 	28 	 CD	O
%  	%  	 NN	O
reported  	reported  	 VBD	O
using  	using  	 VBG	O
a  	a  	 DT	O
less-effective  	less-effective  	 JJ	B-NP
alternative  	alternative  	 NN	I-NP
because  	because  	 IN	O
of  	of  	 IN	O
a  	a  	 DT	O
shortage 	shortage 	 NN	O
.  	.  	 .	O
Although  	Although  	 IN	O
physician  	physician  	 JJ	O
demographic  	demographic  	 JJ	B-NP
characteristics  	characteristics  	 NNS	I-NP
did  	did  	 VBD	O
not  	not  	 RB	O
predict  	predict  	 VB	O
reports  	reports  	 NNS	O
of  	of  	 IN	O
drug  	drug  	 NN	B-NP
shortages 	shortages 	 NNS	I-NP
,  	,  	 ,	O
practice  	practice  	 NN	B-NP
characteristics  	characteristics  	 NNS	I-NP
did 	did 	 VBD	O
.  	.  	 .	O
Veterans  	Veterans  	 NNP	B-NP
Affairs  	Affairs  	 NNP	I-NP
( 	( 	 -LRB-	O
VA 	VA 	 NNP	B-NP
)  	)  	 -RRB-	O
oncologists  	oncologists  	 NN	B-NP
were  	were  	 VBD	O
less  	less  	 RBR	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
report  	report  	 VB	O
experiencing  	experiencing  	 VBG	O
any  	any  	 DT	O
shortage  	shortage  	 NN	O
than  	than  	 IN	O
oncologists  	oncologists  	 NN	B-NP
in  	in  	 IN	O
single-specialty  	single-specialty  	 JJ	B-NP
group  	group  	 NN	I-NP
practice  	practice  	 NN	I-NP
( 	( 	 -LRB-	O
odds  	odds  	 JJ	B-NP
ratio  	ratio  	 NN	I-NP
[ 	[ 	 -LRB-	O
OR 	OR 	 NNP	B-NP
] 	] 	 -RRB-	O
,  	,  	 ,	O
0.4 	0.4 	 CD	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
0.2  	0.2  	 CD	O
to  	to  	 TO	O
0.9 	0.9 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
reported  	reported  	 JJ	O
use  	use  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
less  	less  	 RBR	O
effective  	effective  	 JJ	O
alternative  	alternative  	 NN	O
to  	to  	 TO	O
any  	any  	 DT	O
drug  	drug  	 NN	O
was  	was  	 VBD	O
also  	also  	 RB	O
less  	less  	 RBR	O
common  	common  	 JJ	O
among  	among  	 IN	O
VA  	VA  	 NNP	B-NP
oncologists  	oncologists  	 NNS	I-NP
( 	( 	 -LRB-	O
OR 	OR 	 NNP	O
,  	,  	 ,	O
0.3 	0.3 	 CD	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
0.1  	0.1  	 CD	O
to  	to  	 TO	O
0.9 	0.9 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
oncologists  	oncologists  	 VB	O
affiliated  	affiliated  	 VBN	O
with  	with  	 IN	O
health  	health  	 NN	B-NP
maintenance  	maintenance  	 NN	I-NP
organizations  	organizations  	 NNS	I-NP
( 	( 	 -LRB-	O
OR 	OR 	 NNP	O
,  	,  	 ,	O
0.4 	0.4 	 CD	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
0.2  	0.2  	 CD	O
to  	to  	 TO	O
0.9 	0.9 	 CD	O
)  	)  	 -RRB-	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
physicians  	physicians  	 NNS	O
in  	in  	 IN	O
single-specialty  	single-specialty  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
.  	.  	 .	O
Most  	Most  	 RBS	O
oncologists  	oncologists  	 JJ	B-NP
encountered  	encountered  	 JJ	I-NP
drug  	drug  	 NN	I-NP
shortages  	shortages  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
year  	year  	 NN	O
before  	before  	 IN	O
our  	our  	 PRP$	O
survey 	survey 	 NN	O
,  	,  	 ,	O
but  	but  	 CC	O
experiences  	experiences  	 NNS	O
with  	with  	 IN	O
shortages  	shortages  	 NNS	O
varied  	varied  	 VBN	O
with  	with  	 IN	O
practice  	practice  	 NN	B-NP
structure 	structure 	 NN	I-NP
.  	.  	 .	O
Further  	Further  	 JJ	B-NP
research  	research  	 NN	I-NP
is  	is  	 VBZ	O
needed  	needed  	 VBN	O
to  	to  	 TO	O
quantitatively  	quantitatively  	 VB	O
assess  	assess  	 VB	O
the  	the  	 DT	O
impact  	impact  	 NN	O
of  	of  	 IN	O
drug  	drug  	 NN	B-NP
shortages  	shortages  	 NNS	I-NP
on  	on  	 IN	O
patients  	patients  	 NNS	O
and  	and  	 CC	O
evaluate  	evaluate  	 VB	O
various  	various  	 JJ	O
strategies  	strategies  	 NNS	O
for  	for  	 IN	O
managing  	managing  	 VBG	O
them 	them 	 PRP	O
.  	.  	 .	O
